Navitrux Injection, Powder, Lyophilized, For Solution
NDC Package 83831-153-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Navitrux (fosaprepitant) injection is fosaprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Avyxa Pharma, Llc, this product is identified by NDC 83831-153 and is authorized under FDA application NDA220436.

Identification & Billing

NDC Package Code
83831-153-01
Package Description
1 VIAL in 1 CARTON / 5 mL in 1 VIAL
Product Code
83831-153
11-Digit Billing Format
83831015301

Clinical Specifications

Proprietary Name
Navitrux
Non-Proprietary Name
Fosaprepitant
Substance Name
Fosaprepitant Dimeglumine
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
FOSAPREPITANT DIMEGLUMINE 150 mg/5mL
Pharmacologic Class
Usage Information
Fosaprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). Fosaprepitant works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting. This medication will not treat nausea or vomiting that has already started. Ask your doctor what you should do if you already have nausea or vomiting.

Regulatory & Marketing

Labeler Name
Avyxa Pharma, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA220436
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-24-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 83831-153-01 identifies a specific commercial package of 1 vial in 1 carton / 5 ml in 1 vial of Navitrux, a human prescription drug labeled by Avyxa Pharma, Llc. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains fosaprepitant dimeglumine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Avyxa Pharma, Llc on June 24, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Fosaprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). Fosaprepitant works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting. This medication will not treat nausea or vomiting that has already started. Ask your doctor what you should do if you already have nausea or vomiting.

How is this Avyxa Pharma, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 83831015301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
83831-153-01
11-Digit CMS (5-4-2)
83831-0153-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.